Table 3 BTK inhibitors for relapsed or refractory mantle cell lymphoma
Parameter | Ibrutinib | Acalabrutinib | Zanubrutinib | Orelabrutinib | LOXO-305 |
|---|---|---|---|---|---|
Patients (n) | 111 | 124 | 86 | 97 (106) | 38 |
Age (years) | 68 | 68 | 60.5 | NA | 69 |
Prior SCT | 11% | 18% | 3.5% | NA | 25% |
Prior BTKi | NA | NA | NA | NA | 93% |
ORR | 67% | 80% | 84% | 87.9% | 52% |
CR | 23% | 40% | 67.5% | 27.4% | 25% |
DOR (months) | 17.5 | 25.7 | 19.5 | NR | NR |
Median PFS (months) | 13.0 | NR | 22.1 | NR | NR |
Median OS %, months | 47%, 24 | 87%, 12 | 84%, 12 | 88.7%, 12 | NR |
New A Fib | 11% | 0% | 0% | 0% | < 1% |
Neutropenia, severe | 17% | 11% | 19.8% | NA | NA |
Pneumonia, severe | 6% | 6% | 9.3% | NA | NA |
Bleeding, severe | 6% | 2.4% | 2.3% | 0 | < 1% |
Reference | [40] | [39] | [38] | [37] | [41] |